Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of High Dose Inorganic seLenium for Preventing Chemotherapy Induced pEripheral Neuropathy in platINUM Sensitive Recurrent Ovarian, Fallopian, Primary Peritoneal Cancer: Phase III Randomised Controlled Trial

NCT04201561 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT04201561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04201561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of High Dose Inorganic seLenium for Preventing Chemotherapy Induced pEripheral Neuropathy in platINUM Sensitive Recurrent Ovarian, Fallopian, Primary Peritoneal Cancer: Phase III Randomised Controlled Trial
Lead sponsor
Seoul National University Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
December 24, 2019
Completion date
December 31, 2024
Enrollment
68 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced peripheral neuropathy, fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma, recurrent ovarian carcinoma